Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 429

1.

Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway.

Ng L, Chow AKM, Man JHW, Yau TCC, Wan TMH, Iyer DN, Kwan VHT, Poon RTP, Pang RWC, Law WL.

BMC Cancer. 2018 Jun 1;18(1):621. doi: 10.1186/s12885-018-4326-5.

2.

Prevention of post-sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial.

Leung WK, But DY, Wong SY, Tong TS, Liu KS, Cheung KS, Tsang SH, Chok KS, Poon RT, Hung IF.

J Dig Dis. 2018 Jun;19(6):369-376. doi: 10.1111/1751-2980.12604. Epub 2018 May 24.

PMID:
29722146
3.

Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma.

Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, Yuen J, Poon RTP, Fan ST, Lo CM.

Br J Surg. 2017 Dec;104(13):1775-1784. doi: 10.1002/bjs.10677. Epub 2017 Nov 1.

PMID:
29091283
4.

Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.

Shek FH, Luo R, Lam BYH, Sung WK, Lam TW, Luk JM, Leung MS, Chan KT, Wang HK, Chan CM, Poon RT, Lee NP.

Cell Oncol (Dordr). 2017 Oct;40(5):443-456. doi: 10.1007/s13402-017-0332-x. Epub 2017 Jun 19.

PMID:
28631187
5.

Emergence of CD26+ Cancer Stem Cells with Metastatic Properties in Colorectal Carcinogenesis.

Cheung AH, Iyer DN, Lam CS, Ng L, Wong SKM, Lee HS, Wan T, Man J, Chow AKM, Poon RT, Pang R, Law WL.

Int J Mol Sci. 2017 May 23;18(6). pii: E1106. doi: 10.3390/ijms18061106.

6.

Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma?

Yip VS, Cheung TT, Poon RT, Yau T, Fung J, Dai WC, Chan AC, Chok SH, Chan SC, Lo CM.

Transl Gastroenterol Hepatol. 2016 Jun 14;1:51. doi: 10.21037/tgh.2016.05.11. eCollection 2016.

7.

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.

Ho DWH, Chan LK, Chiu YT, Xu IMJ, Poon RTP, Cheung TT, Tang CN, Tang VWL, Lo ILO, Lam PWY, Yau DTW, Li MX, Wong CM, Ng IOL.

Gut. 2017 Aug;66(8):1496-1506. doi: 10.1136/gutjnl-2016-312734. Epub 2016 Dec 14.

8.

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RTP, Bottaro DP.

Clin Cancer Res. 2017 May 15;23(10):2405-2413. doi: 10.1158/1078-0432.CCR-16-1789. Epub 2016 Nov 7.

9.

Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT, Kokudo N.

Liver Cancer. 2016 Oct;5(4):245-256. Epub 2016 Sep 14.

10.

Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.

Cheung AH, Lam CS, Tam HS, Cheung TT, Pang R, Poon RT.

Hepatobiliary Pancreat Dis Int. 2016 Oct;15(5):493-498.

PMID:
27733318
11.

Corrigendum to "Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma" [J Hepatol 2015;62:607-616].

Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, Ng KT, Forbes SJ, Guan XY, Poon RT, Fan ST, Man K.

J Hepatol. 2016 Jun;64(6):1461. doi: 10.1016/j.jhep.2016.02.038. Epub 2016 Mar 16. No abstract available.

PMID:
27198050
12.

Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.

Zhu AX, Chen D, He W, Kanai M, Voi M, Chen LT, Daniele B, Furuse J, Kang YK, Poon RT, Vogel A, Chiang DY.

J Hepatol. 2016 Aug;65(2):296-304. doi: 10.1016/j.jhep.2016.04.015. Epub 2016 Apr 27.

PMID:
27130844
13.

Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.

Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT.

Hepatology. 2016 Sep;64(3):774-84. doi: 10.1002/hep.28600. Epub 2016 May 17.

PMID:
27082062
14.

Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma.

Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhim G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V; Chieh Chiang, on behalf of the EORTC Quality of Life Group.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e304-e311. doi: 10.1111/ajco.12464. Epub 2016 Apr 1.

PMID:
27038366
15.

Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma.

Zhang AY, Lai CL, Poon RT, Huang FY, Seto WK, Fung J, Wong DK, Yuen MF.

J Gastroenterol Hepatol. 2016 Sep;31(9):1638-45. doi: 10.1111/jgh.13316.

PMID:
26905957
16.

Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma.

Hung IF, Wong DK, Poon RT, Fong DY, Chui AH, Seto WK, Fung JY, Chan AC, Yuen JC, Tiu R, Choi O, Lai CL, Yuen MF.

PLoS One. 2016 Feb 22;11(2):e0148493. doi: 10.1371/journal.pone.0148493. eCollection 2016.

17.

Acute pancreatitis induced by transarterial chemoembolization: a single-center experience of over 1500 cases.

She WH, Chan AC, Cheung TT, Chok KSh, Chan SC, Poon RT, Lo CM.

Hepatobiliary Pancreat Dis Int. 2016 Feb;15(1):93-8.

PMID:
26818549
18.

Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.

Koh PS, Chan AC, Cheung TT, Chok KS, Dai WC, Poon RT, Lo CM.

HPB (Oxford). 2016 Jan;18(1):72-8. doi: 10.1016/j.hpb.2015.07.005.

19.

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma.

Lee VH, Leung DK, Luk MY, Tong CC, Law MW, Ng SC, Wong KK, Poon RT, Kwong DL, Leung TW.

Onco Targets Ther. 2015 Nov 20;8:3457-64. doi: 10.2147/OTT.S92473. eCollection 2015.

20.

Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.

Koh PS, Chan AC, Cheung TT, Chok KS, Dai WC, Poon RT, Lo CM.

HPB (Oxford). 2015 Oct 16. doi: 10.1111/hpb.12495. [Epub ahead of print]

PMID:
26473770
21.

A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma.

Chow AK, Yau TC, Ng L, Chu AC, Law WL, Poon RT, Pang RW.

Am J Cancer Res. 2015 Jul 15;5(8):2376-86. eCollection 2015.

22.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators.

Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.

PMID:
26361969
23.

Pure Laparoscopic Versus Open Left Lateral Sectionectomy for Hepatocellular Carcinoma: A Single-Center Experience.

Cheung TT, Poon RT, Dai WC, Chok KS, Chan SC, Lo CM.

World J Surg. 2016 Jan;40(1):198-205. doi: 10.1007/s00268-015-3237-8.

PMID:
26316115
24.

Modified Anterior Approach for the ALPPS Procedure: How We Do It.

Chan AC, Poon RT, Lo CM.

World J Surg. 2015 Nov;39(11):2831-5. doi: 10.1007/s00268-015-3174-6.

PMID:
26239774
25.

Comparison of Survival Outcomes Between Right Posterior Sectionectomy and Right Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Liver: A Single-Centre Experience.

Yip VS, Poon RT, Chok KS, Chan AC, Dai WC, Tsang SH, Chan SC, Lo CM, Cheung TT.

World J Surg. 2015 Nov;39(11):2764-70. doi: 10.1007/s00268-015-3146-x.

PMID:
26154577
26.

Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer.

Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, Yau TC, Lo O, Foo CC, Poon JT, Poon RT, Pang R, Law WL.

Stem Cells Int. 2015;2015:247892. doi: 10.1155/2015/247892. Epub 2015 May 27.

27.

Safety of ALPPS Procedure by the Anterior Approach for Hepatocellular Carcinoma.

Chan AC, Poon RT, Chan C, Lo CM.

Ann Surg. 2016 Feb;263(2):e14-6. doi: 10.1097/SLA.0000000000001272. No abstract available.

PMID:
26079914
28.

Technical considerations for ligation of ruptured hepatic artery aneurysm: is arterial reconstruction necessary?

Lam S, Chan AC, Poon RT.

Hong Kong Med J. 2015 Jun;21(3):276-9. doi: 10.12809/hkmj144260.

29.

Hong Kong consensus recommendations on the management of hepatocellular carcinoma.

Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC, Cheung FY, Loo CK, But YK, Hsu SJ, Yu SC, Yau T.

Liver Cancer. 2015 Mar;4(1):51-69. doi: 10.1159/000367728. Review.

30.

Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer.

Ng L, Wan TM, Lam CS, Chow AK, Wong SK, Man JH, Li HS, Cheng NS, Pak RC, Cheung AH, Yau TC, Lo OS, Foo DC, Poon JT, Poon RT, Pang RW, Law WL.

PLoS One. 2015 May 11;10(5):e0126219. doi: 10.1371/journal.pone.0126219. eCollection 2015.

31.

Quality of life changes in patients undergoing treatment for hepatocellular carcinoma.

Chie WC, Yu F, Li M, Baccaglini L, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V, Chiang C.

Qual Life Res. 2015 Oct;24(10):2499-506. doi: 10.1007/s11136-015-0985-8. Epub 2015 May 6.

PMID:
25943170
32.

Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer.

Yung MK, Lo KW, Yip CW, Chung GT, Tong CY, Cheung PF, Cheung TT, Poon RT, So S, Fan ST, Cheung ST.

BMC Cancer. 2015 Apr 11;15:264. doi: 10.1186/s12885-015-1294-x.

33.

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.

Yau T, Cheng PN, Chan P, Chen L, Yuen J, Pang R, Fan ST, Wheatley DN, Poon RT.

Invest New Drugs. 2015 Apr;33(2):496-504. doi: 10.1007/s10637-014-0200-8. Epub 2015 Feb 10.

PMID:
25666409
34.

Pancreaticoduodenectomy with vascular reconstruction for adenocarcinoma of the pancreas with borderline resectability.

Cheung TT, Poon RT, Chok KS, Chan AC, Tsang SH, Dai WC, Chan SC, Fan ST, Lo CM.

World J Gastroenterol. 2014 Dec 14;20(46):17448-55. doi: 10.3748/wjg.v20.i46.17448.

35.

Genome-wide identification of RNA editing in hepatocellular carcinoma.

Kang L, Liu X, Gong Z, Zheng H, Wang J, Li Y, Yang H, Hardwick J, Dai H, Poon RT, Lee NP, Mao M, Peng Z, Chen R.

Genomics. 2015 Feb;105(2):76-82. doi: 10.1016/j.ygeno.2014.11.005. Epub 2014 Nov 25.

36.

Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma.

Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, Ng KT, Forbes SJ, Guan XY, Poon RT, Fan ST, Man K.

J Hepatol. 2015 Mar;62(3):607-16. doi: 10.1016/j.jhep.2014.10.029. Epub 2014 Oct 30.

PMID:
25450711
37.

Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus.

Wong TC, Cheung TT, Chok KS, Chan AC, Dai WC, Chan SC, Poon RT, Fan ST, Lo CM.

HPB (Oxford). 2015 May;17(5):401-8. doi: 10.1111/hpb.12368. Epub 2014 Nov 19.

38.

Recent advances in the prevention of hepatocellular carcinoma recurrence.

Lu LC, Cheng AL, Poon RT.

Semin Liver Dis. 2014 Nov;34(4):427-34. doi: 10.1055/s-0034-1394141. Epub 2014 Nov 4. Review.

PMID:
25369304
39.

Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo.

Cheung PF, Yip CW, Ng LW, Lo KW, Wong N, Choy KW, Chow C, Chan KF, Cheung TT, Poon RT, Fan ST, Cheung ST.

Cancer Cell Int. 2014 Oct 9;14(1):103. doi: 10.1186/s12935-014-0103-y. eCollection 2014.

40.

Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.

Cheung PF, Yip CW, Wong NC, Fong DY, Ng LW, Wan AM, Wong CK, Cheung TT, Ng IO, Poon RT, Fan ST, Cheung ST.

Cancer Immunol Res. 2014 Dec;2(12):1209-19. doi: 10.1158/2326-6066.CIR-14-0096. Epub 2014 Oct 14.

41.

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, Poon RT, Yeo W, Park JW, Tay MH, Hsieh WS, Kappeler C, Rajagopalan P, Krissel H, Jeffers M, Yen CJ, Tak WY.

Clin Cancer Res. 2014 Dec 1;20(23):5976-85. doi: 10.1158/1078-0432.CCR-13-3445. Epub 2014 Oct 7.

42.

Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm.

Dai WC, Cheung TT, Chok KS, Chan AC, Sharr WW, Tsang SH, Yuen WK, Chan SC, Fan ST, Lo CM, Poon RT.

HPB (Oxford). 2015 Mar;17(3):226-31. doi: 10.1111/hpb.12324. Epub 2014 Oct 6.

43.

Retrospective study of metachronous lung metastases from primary hepatocellular carcinoma.

Chok KS, Yau TC, Cheung TT, Poon RT, Lo CM.

ANZ J Surg. 2016 Apr;86(4):289-93. doi: 10.1111/ans.12859. Epub 2014 Sep 29.

PMID:
25267256
44.

Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.

She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, Liu RK, Poon RT, Chan SC, Fan ST, Lo CM.

Hepatobiliary Surg Nutr. 2014 Aug;3(4):185-93. doi: 10.3978/j.issn.2304-3881.2014.07.09.

45.

Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk stratification.

Liu D, Fong DY, Chan AC, Poon RT, Khong PL.

Radiology. 2015 Jan;274(1):133-40. doi: 10.1148/radiol.14132343. Epub 2014 Aug 25.

PMID:
25162308
46.

Education and Imaging. Hepatobiliary and pancreatic: cholangiopathy in ketamine user--an emerging new condition.

Cheung TT, Poon RT, Chan AC, Lo CM.

J Gastroenterol Hepatol. 2014 Sep;29(9):1663. doi: 10.1111/jgh.12682. No abstract available.

PMID:
25154444
47.

Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma.

Ng KT, Xu A, Cheng Q, Guo DY, Lim ZX, Sun CK, Fung JH, Poon RT, Fan ST, Lo CM, Man K.

Mol Cancer. 2014 Aug 22;13:196. doi: 10.1186/1476-4598-13-196.

48.

Little girl who conquered the "ALPPS''.

Chan A, Chung PH, Poon RT.

World J Gastroenterol. 2014 Aug 7;20(29):10208-11. doi: 10.3748/wjg.v20.i29.10208.

49.

The clinicopathological significance of miR-133a in colorectal cancer.

Wan TM, Lam CS, Ng L, Chow AK, Wong SK, Li HS, Man JH, Lo OS, Foo D, Cheung A, Yau T, Poon JT, Poon RT, Law WL, Pang RW.

Dis Markers. 2014;2014:919283. doi: 10.1155/2014/919283. Epub 2014 Jul 1.

50.

Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma.

Or YY, Chow AK, Ng L, Fan ST, Yau TC, Poon RT, Pang RW.

Mol Med Rep. 2014 Oct;10(4):2025-30. doi: 10.3892/mmr.2014.2413. Epub 2014 Jul 22.

PMID:
25070628

Supplemental Content

Support Center